Education
About Us
Working with TipRanks
Follow Us
Mereo Biopharma Group Plc (MREO)
NASDAQ:MREO
MREO Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MREO Stock 12 Month Forecast
Average Price Target
$7.75
▲(170.03%Upside)
| Highest Price Target$10.00 | Average Price Target$7.75 | Lowest Price Target$6.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$10
Buy
248.43%
Upside
Reiterated
06/21/25
J.P. Morgan
―
Buy
―
Reiterated
06/05/25
Needham
$7
Buy
143.90%
Upside
Reiterated
05/22/25
Leerink Partners
$8
Buy
178.75%
Upside
Reiterated
05/13/25
Positive Outlook for Mereo Biopharma Group Plc: Buy Rating Supported by Promising Lead Programs and Strong Financial PositionWe continue to believe it is a matter of when (not if) we see positive data and think the second interim is likely to hit (see our deep dive here). Meanwhile, MREO continues to lay the groundwork to prepare for a successful commercial launch in the UK and EU, including engagement with regulatory/HTA bodies and real- world data collection efforts via the SATURN program. Regarding alvelestat, the company remains in discussion with multiple potential partners for the development and commercialization as start-up activities for the planned single and global pivotal Phase 3 study are ongoing.
BTIG
$6
Buy
109.06%
Upside
Reiterated
05/13/25
Unknown AnalystGoldman Sachs
Not Ranked
Goldman Sachs
$7
Buy
143.90%
Upside
Initiated
03/27/25
Mereo Biopharma ADRs Rated New Overweight at JPMorgan; PT $7
Cantor Fitzgerald
$7
Buy
143.90%
Upside
Reiterated
03/26/25
Jefferies
$7
Buy
143.90%
Upside
Initiated
12/06/24
Robert W. Baird
$8
Buy
178.75%
Upside
Reiterated
11/12/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$10
Buy
248.43%
Upside
Reiterated
06/21/25
J.P. Morgan
―
Buy
―
Reiterated
06/05/25
Needham
$7
Buy
143.90%
Upside
Reiterated
05/22/25
Leerink Partners
$8
Buy
178.75%
Upside
Reiterated
05/13/25
Positive Outlook for Mereo Biopharma Group Plc: Buy Rating Supported by Promising Lead Programs and Strong Financial PositionWe continue to believe it is a matter of when (not if) we see positive data and think the second interim is likely to hit (see our deep dive here). Meanwhile, MREO continues to lay the groundwork to prepare for a successful commercial launch in the UK and EU, including engagement with regulatory/HTA bodies and real- world data collection efforts via the SATURN program. Regarding alvelestat, the company remains in discussion with multiple potential partners for the development and commercialization as start-up activities for the planned single and global pivotal Phase 3 study are ongoing.
BTIG
$6
Buy
109.06%
Upside
Reiterated
05/13/25
Unknown AnalystGoldman Sachs
Not Ranked
Goldman Sachs
$7
Buy
143.90%
Upside
Initiated
03/27/25
Mereo Biopharma ADRs Rated New Overweight at JPMorgan; PT $7
Cantor Fitzgerald
$7
Buy
143.90%
Upside
Reiterated
03/26/25
Jefferies
$7
Buy
143.90%
Upside
Initiated
12/06/24
Robert W. Baird
$8
Buy
178.75%
Upside
Reiterated
11/12/24
Best Analysts Covering Mereo Biopharma Group Plc
1 Month
xxx
Success Rate
5/7 ratings generated profit
Average Return
+14.80%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +14.80% per trade.
3 Months
xxx
Success Rate
12/16 ratings generated profit
Average Return
+15.44%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +15.44% per trade.
1 Year
Success Rate
11/16 ratings generated profit
Average Return
+68.41%
reiterated a buy rating 2 months ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +68.41% per trade.
2 Years
xxx
Success Rate
11/16 ratings generated profit
Average Return
+98.21%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 68.75% of your transactions generating a profit, with an average return of +98.21% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MREO Analyst Recommendation Trends
Rating
Jan 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
8
13
13
16
10
Buy
1
0
0
0
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
13
13
16
11
Each month's total comprises the sum of three months' worth of ratings.
MREO Financial Forecast
MREO Stock Forecast FAQ
What is MREO’s average 12-month price target, according to analysts?
Based on analyst ratings, Mereo Biopharma Group Plc’s 12-month average price target is 7.75.
What is MREO’s upside potential, based on the analysts’ average price target?
Mereo Biopharma Group Plc has 170.03% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MREO a Buy, Sell or Hold?
Mereo Biopharma Group Plc has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Mereo Biopharma Group Plc’s price target?
The average price target for Mereo Biopharma Group Plc is 7.75. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $6.00. The average price target represents 170.03% Increase from the current price of $2.87.
The highest analyst price target is $10.00 ,the lowest forecast is $6.00. The average price target represents 170.03% Increase from the current price of $2.87.
What do analysts say about Mereo Biopharma Group Plc?
Mereo Biopharma Group Plc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of MREO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.